MARKET

JAZZ

JAZZ

Jazz Pharmaceuticals Plc
NASDAQ
236.28
+1.40
+0.60%
After Hours: 236.41 +0.13 +0.06% 19:30 09/24 EDT
OPEN
235.82
PREV CLOSE
234.88
HIGH
236.52
LOW
232.00
VOLUME
551.32K
TURNOVER
--
52 WEEK HIGH
266.38
52 WEEK LOW
125.79
MARKET CAP
15.34B
P/E (TTM)
16.16
1D
5D
1M
3M
1Y
5Y
1D
Jazz Pharmaceuticals Price Target Announced at $337.00/Share by Goldman Sachs
Dow Jones · 13h ago
Goldman Sachs Reinstates Buy on Jazz Pharmaceuticals, Announces $337 Price Target
Benzinga · 14h ago
Goldman Sachs Resumes Coverage with a Buy Rating on Jazz Pharmaceuticals (JAZZ)
TipRanks · 18h ago
Jazz Pharmaceuticals Refinances Term Loan, Extends Maturities
TipRanks · 1d ago
Jazz Pharmaceuticals (JAZZ) Gains Put Its Valuation Story Back In Focus
Simply Wall St · 1d ago
Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development
Benzinga · 3d ago
Weekly Report: what happened at JAZZ last week (0914-0918)?
Weekly Report · 3d ago
FDA, Duke-Margolis workshop to examine evidence standards for rare diseases
Seeking Alpha · 4d ago
More
About JAZZ
Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, ABS-1230, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.

Webull offers Jazz Pharmaceuticals PLC stock information, including NASDAQ: JAZZ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAZZ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAZZ stock methods without spending real money on the virtual paper trading platform.